AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: GLORIA LAU
Every year, thousands of people quit taking their osteoporosis drugs.
Half of them quit because of the side effects. The other half quit because they don't see any benefits.
A new bone-building drug under development might change all that.
The drug, Boniva, is being co-developed by Roche and GlaxoSmithKline. It awaits review by the Food and Drug Administration and regulators in the European Union.
Boniva, expected to reach pharmacies by mid to late next year, is a bisphosphonate drug. It works nearly the same way as two soon-to-be rival medicines: Fosamax, marketed by Merck; and Actonel, co-marketed by Aventis and Procter & Gamble.
The big difference is that Boniva is a once-a-month tablet, while Fosamax and Actonel are weekly tablets.